118 related articles for article (PubMed ID: 3607762)
1. Pediatric Oncology Group Study of in vitro clonal growth patterns of leukemic cells in childhood acute nonlymphocytic leukemia as a predictor of induction response.
Findley HW; Steuber CP; Krischer JP; Ragab AH
Cancer Res; 1987 Aug; 47(15):4225-8. PubMed ID: 3607762
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to chemotherapy in acute leukemia by in vitro drug sensitivity testing on leukemic stem cells.
Gustavsson A; Olofsson T
Cancer Res; 1984 Oct; 44(10):4648-52. PubMed ID: 6590116
[TBL] [Abstract][Full Text] [Related]
3. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
[TBL] [Abstract][Full Text] [Related]
4. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
Clin Cancer Res; 1999 Sep; 5(9):2491-7. PubMed ID: 10499624
[TBL] [Abstract][Full Text] [Related]
5. Relationship of the growth of leukemic cells in vitro to the outcome of therapy for acute nonlymphocytic leukemia.
Preisler HD; Azarnia N; Marinello M
Cancer Res; 1984 Apr; 44(4):1712-7. PubMed ID: 6704977
[TBL] [Abstract][Full Text] [Related]
6. [Improved results of treatment in 30 cases of acute nonlymphocytic leukemia in childhood].
Imashuku S; Arakawa S; Todo S; Esumi N; Tsunamoto K; Hashida T; Morioka Y; Hibi S; Nagai T; Fujiwara F
Gan To Kagaku Ryoho; 1986 Aug; 13(8):2581-7. PubMed ID: 3740859
[TBL] [Abstract][Full Text] [Related]
7. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
[TBL] [Abstract][Full Text] [Related]
8. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
[TBL] [Abstract][Full Text] [Related]
9. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study.
Steuber CP; Civin C; Krischer J; Culbert S; Ragab A; Ruymann FB; Ravindranath Y; Leventhal B; Wilkinson R; Vietti TJ
J Clin Oncol; 1991 Feb; 9(2):247-58. PubMed ID: 1988573
[TBL] [Abstract][Full Text] [Related]
10. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
11. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
12. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
[TBL] [Abstract][Full Text] [Related]
13. Remission-induction regimens in acute nonlymphocytic leukemia.
Brennan DC; Lewis JP
West J Med; 1980 Oct; 133(4):279-88. PubMed ID: 7347042
[TBL] [Abstract][Full Text] [Related]
14. Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.
Bern MM; Wallach SR; Arkin CF; Lokich JJ; Huberman MS; Anderson NR; Corkery JC; Paul SD; Phillips DF; Sonneborn HA
Cancer Treat Rep; 1987 Feb; 71(2):201-3. PubMed ID: 3802115
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of acute nonlymphocytic leukemia induction chemotherapy in acute lymphocytic leukemia.
Cassileth PA; Bennett JM
Cancer Treat Rep; 1985 Dec; 69(12):1439-40. PubMed ID: 3865702
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy sensitivity assessment of leukemic colony-forming cells with in vitro simultaneous exposure to multiple drugs: clinical correlations in acute nonlymphocytic leukemia.
Park CH; Amare M; Morrison FS; Maloney TR; Goodwin JW
Cancer Treat Rep; 1982 Jun; 66(6):1257-61. PubMed ID: 7083232
[TBL] [Abstract][Full Text] [Related]
18. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
[TBL] [Abstract][Full Text] [Related]
19. Management of acute promyelocytic leukemia relapse in the ATRA era.
Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
[TBL] [Abstract][Full Text] [Related]
20. Combination of 6-mercaptopurine, vincristine, methotrexate, and prednisone in resistant or relapsed acute nonlymphoid leukemia.
Leone G; Pagano L; Marra R; Landolfi R; Cudillo L; Storti S; Mango G; Alfano G; D'Onofrio G
Cancer Treat Rep; 1987; 71(7-8):751-3. PubMed ID: 3607785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
